{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:14:43Z","timestamp":1794060883293,"version":"4.8.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002630","name":"Ewha Womans University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002630","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["21173MFDS562"],"award-info":[{"award-number":["21173MFDS562"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2019M3A9H1103786"],"award-info":[{"award-number":["2019M3A9H1103786"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2022M3E5F1081328"],"award-info":[{"award-number":["2022M3E5F1081328"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003705","name":"Korea Institute of Toxicology","doi-asserted-by":"publisher","award":["1711133848"],"award-info":[{"award-number":["1711133848"]}],"id":[{"id":"10.13039\/501100003705","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1I1A2044117"],"award-info":[{"award-number":["2021R1I1A2044117"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.omtn.2023.102050","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T15:38:55Z","timestamp":1696693135000},"page":"102050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["In\u00a0vivo genome editing using 244-cis LNPs and low-dose AAV achieves therapeutic threshold in hemophilia A mice"],"prefix":"10.1016","volume":"34","author":[{"given":"Jeong Pil","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Yoon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geon Seong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Ri","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeongjin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Sik","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haeshin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-8473","authenticated-orcid":false,"given":"Hyukjin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9491-5740","authenticated-orcid":false,"given":"Su Cheong","family":"Yeom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2023.102050_bib1","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(11)61139-2","article-title":"Modern haemophilia care","volume":"379","author":"Berntorp","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2023.102050_bib2","first-page":"165","article-title":"Prophylaxis in haemophilia should be life-long","volume":"10","author":"Makris","year":"2012","journal-title":"Blood Transfus"},{"key":"10.1016\/j.omtn.2023.102050_bib3","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1111\/jth.12929","article-title":"Half-life extended factor VIII for the treatment of hemophilia A","volume":"13","author":"Tiede","year":"2015","journal-title":"J.\u00a0Thromb. Haemostasis"},{"key":"10.1016\/j.omtn.2023.102050_bib4","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/ajh.25844","article-title":"The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States","volume":"95","author":"Malec","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.omtn.2023.102050_bib5","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/hae.13747","article-title":"Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies","volume":"25","author":"Volkers","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.omtn.2023.102050_bib6","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"124","author":"Kempton","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.102050_bib7","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2516.2007.01518.x","article-title":"European study on orthopaedic status of haemophilia patients with inhibitors","volume":"13","author":"Morfini","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.omtn.2023.102050_bib8","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/14712598.2022.2002842","article-title":"Hemophilia A gene therapy: current and next-generation approaches","volume":"22","author":"Pipe","year":"2022","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.omtn.2023.102050_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/hematology.2021000253","article-title":"Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?","volume":"2021","author":"Ellsworth","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.omtn.2023.102050_bib10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2741\/4324","article-title":"Gene therapy for hemophilia","volume":"20","author":"Rogers","year":"2015","journal-title":"Front. Biosci."},{"key":"10.1016\/j.omtn.2023.102050_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.102050_bib12","doi-asserted-by":"crossref","first-page":"14082","DOI":"10.1073\/pnas.93.24.14082","article-title":"Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein","volume":"93","author":"Kessler","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2023.102050_bib13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"Weyand","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.102050_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12185-018-2548-6","article-title":"Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia","volume":"111","author":"Chowdary","year":"2020","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.omtn.2023.102050_bib15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MOH.0000000000000364","article-title":"Targeting activated protein C to treat hemophilia","volume":"24","author":"Polderdijk","year":"2017","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.omtn.2023.102050_bib16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.102050_bib17","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.15270","article-title":"Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran - results of the phase 1 inhibitor cohort","volume":"19","author":"Pasi","year":"2021","journal-title":"J.\u00a0Thromb. Haemostasis"},{"key":"10.1016\/j.omtn.2023.102050_bib18","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtn.2023.102050_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj6901","article-title":"In\u00a0vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy","volume":"8","author":"Han","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2023.102050_bib20","article-title":"Hemophilia A ameliorated in mice by CRISPR-based in\u00a0vivo genome editing of human Factor VIII","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2023.102050_bib21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.omtn.2022.08.002","article-title":"Genome editing-mediated knock-in of therapeutic genes ameliorates the disease phenotype in a model of hemophilia","volume":"29","author":"Lee","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2023.102050_bib22","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1093\/nar\/gkx154","article-title":"Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery","volume":"45","author":"Gaj","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2023.102050_bib23","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1038\/s41467-022-34898-y","article-title":"Low-dose AAV-CRISPR-mediated liver-specific knock-in restored hemostasis in neonatal hemophilia B mice with subtle antibody response","volume":"13","author":"He","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2023.102050_bib24","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human Immune Responses to Adeno-Associated Virus (AAV) Vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2023.102050_bib25","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41587-020-0642-9","article-title":"High-dose AAV gene therapy deaths","volume":"38","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2023.102050_bib26","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: An integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.102050_bib27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtn.2023.102050_bib28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.omtn.2023.102050_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10556","article-title":"Novel piperazine-based ionizable lipid nanoparticles allow the repeated dose of mRNA to fibrotic lungs with improved potency and safety","author":"Kim","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.omtn.2023.102050_bib30","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study","volume":"137","author":"Klamroth","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.102050_bib31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd.2018.70","article-title":"Advances and innovations in haemophilia treatment","volume":"17","author":"Peters","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2023.102050_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/cr.2017.76","article-title":"Homology-mediated end joining-based targeted integration using CRISPR\/Cas9","volume":"27","author":"Yao","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.omtn.2023.102050_bib33","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109256118","article-title":"On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2023.102050_bib34","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.102050_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/biology10080704","article-title":"Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion","volume":"10","author":"Han","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.omtn.2023.102050_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21113747","article-title":"High Homology-Directed Repair Using Mitosis Phase and Nucleus Localizing Signal","volume":"21","author":"Han","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2023.102050_bib37","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.04766","article-title":"Enhanced homology-directed human genome engineering by controlled timing of CRISPR\/Cas9 delivery","volume":"3","author":"Lin","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.omtn.2023.102050_bib38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2478\/s11658-014-0188-2","article-title":"Study on the activity of the signaling pathways regulating hepatocytes from G0 phase into G1 phase during rat liver regeneration","volume":"19","author":"Li","year":"2014","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.omtn.2023.102050_bib39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors","volume":"21","author":"Daya","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.omtn.2023.102050_bib40","doi-asserted-by":"crossref","first-page":"13104","DOI":"10.1073\/pnas.0702778104","article-title":"Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction","volume":"104","author":"Wang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2023.102050_bib41","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.102050_bib42","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2023.102050_bib43","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1182\/blood.V84.7.2197.2197","article-title":"Analysis of intron 22 inversions of the factor VIII gene in severe hemophilia A: implications for genetic counseling","volume":"84","author":"Jenkins","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.102050_bib44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/hum.2019.274","article-title":"Adeno-Associated Virus Serotype-Specific Inverted Terminal Repeat Sequence Role in Vector Transgene Expression","volume":"31","author":"Earley","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2023.102050_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bjhh.2017.03.009","article-title":"Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations","volume":"39","author":"Duarte","year":"2017","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"10.1016\/j.omtn.2023.102050_bib46","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s40265-022-01788-y","article-title":"Valoctocogene Roxaparvovec: First Approval","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2023.102050_bib47","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.transci.2019.08.008","article-title":"Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time","volume":"58","author":"Nakar","year":"2019","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.omtn.2023.102050_bib48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s13204-020-01558-w","article-title":"Direct imaging of antigen-antibody binding by atomic force microscopy","volume":"11","author":"Hu","year":"2021","journal-title":"Appl. Nanosci."},{"key":"10.1016\/j.omtn.2023.102050_bib49","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1089\/hum.2016.128","article-title":"Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice","volume":"28","author":"Greig","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2023.102050_bib50","doi-asserted-by":"crossref","first-page":"19587","DOI":"10.1074\/jbc.274.28.19587","article-title":"Expression of factor VIII by murine liver sinusoidal endothelial cells","volume":"274","author":"Do","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2023.102050_bib51","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13059-019-1907-9","article-title":"Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse","volume":"20","author":"Zhang","year":"2019","journal-title":"Genome Biol."},{"key":"10.1016\/j.omtn.2023.102050_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ph15101183","article-title":"Updates on Novel Non-Replacement Drugs for Hemophilia","volume":"15","author":"Gualtierotti","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omtn.2023.102050_bib53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.18379","article-title":"Current and future therapies for haemophilia-Beyond factor replacement therapies","volume":"200","author":"Nogami","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omtn.2023.102050_bib54","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.102050_bib55","doi-asserted-by":"crossref","first-page":"12196","DOI":"10.1021\/ja0474906","article-title":"Charge-reversal amphiphiles for gene delivery","volume":"126","author":"Prata","year":"2004","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2023.102050_bib56","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.102050_bib57","doi-asserted-by":"crossref","first-page":"25481","DOI":"10.1021\/acsami.7b08163","article-title":"Biodegradable Amino-Ester Nanomaterials for Cas9 mRNA Delivery in\u00a0Vitro and in\u00a0Vivo","volume":"9","author":"Zhang","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.omtn.2023.102050_bib58","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A Single Administration of CRISPR\/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In\u00a0Vivo Genome Editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2023.102050_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658038","article-title":"Immunomodulation in Administration of rAAV: Preclinical and Clinical Adjuvant Pharmacotherapies","volume":"12","author":"Chu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2023.102050_bib60","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2023.102050_bib61","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ymthe.2020.10.018","article-title":"Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.102050_bib62","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2023.102050_bib63","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In\u00a0Vivo Gene Editing for Transthyretin Amyloidosis. Reply","volume":"385","author":"Gillmore","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2023.102050_bib64","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/nbt.4005","article-title":"Structure-guided chemical modification of guide RNA enables potent non-viral in\u00a0vivo genome editing","volume":"35","author":"Yin","year":"2017","journal-title":"Nat. Biotechnol."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123002688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123002688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T01:23:20Z","timestamp":1744507400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253123002688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":64,"alternative-id":["S2162253123002688"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2023.102050","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vivo genome editing using 244-cis LNPs and low-dose AAV achieves therapeutic threshold in hemophilia A mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2023.102050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"102050"}}